InvestorsHub Logo
Followers 68
Posts 823
Boards Moderated 0
Alias Born 03/19/2009

Re: Potse post# 4413

Wednesday, 02/08/2023 8:33:54 PM

Wednesday, February 08, 2023 8:33:54 PM

Post# of 5923
HLTT(.288)...2022 investors presentation is interesting......

Based on the wording in the shareholder letter it appears that 2022 Q4 revenue for the wound care business was at a minimum over $2.3M (compared to $766K in 2022 Q3), and there is an expectation that revenue for that business will continue growing in 2023. The uplisting process to one of the higher exchanges is expected to start after HLTT files its 2022 10-K.



A link to a 2022 investors presentation was posted over on the HLTT board. It looks like the presentation was from around August/September, and it contains some pretty interesting information regarding the revenue of World Reach Health, anticipated revenue for the wound care business, existing and possible products/investments for HLTT, etc.

The revenue numbers of World Reach Health (I assume through the first 3 quarters of 2022) and the semi-guidance for the wound care business are eye catching. If those numbers are anywhere close to being accurate and indicative of what HLTT might expect going forward, calendar 2023 could turn out to be quite an interesting time for HLTT. Some items of interest from the presentation.......

Page 6:

Healthtech acquired a majority-controlled interest in its long-standing affiliate, World Reach Health, and adds over $60M in sales YTD to its revenue portfolio.



Page 32:

Over 15,000 cm2 of allograft products in inventory (value of approximately $10M), with the product launching in August 2022, the inventory alone is anticipated to generate over $40M in receivables within twelve months.



Page 33 (Endura-Kit):

Healthtech intends to invest $2M to acquire partial ownership in the manufacturing entity, and will also secure semi-exclusive distribution rights to the product around the globe. The post-operative pain therapeutics market is estimated to be around $35B, and Healthtech has an opportunity to introduce a market-shifting product that can achieve 4% market capture within 5 years, which translates to over $2B in annual revenues.



https://pdf.ac/2a2YYW

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.